Simon D. Roger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Simon D. Roger has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Adeera Levin
1 shared publicationAlan Parnham
1 shared publicationAlex Disney
1 shared publicationAnthony Clarkson
1 shared publicationBruce Cooper
Department of Renal Medicine, Gosford Hospital, Gosford, New South Wales, Australia
1 shared publication- Carmel Mary Hawley
Australasian Kidney Trials Network (AKTN), The University of Queensland, Brisbane, Queensland, Australia
1 shared publication
Latest Publications
- 1 August 2004
- Published by Wiley in Nephrology
- Vol. 9 (4) , 223-228
What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials?
SUMMARY: Background: The recommended conversion dose for changing from epoetin alfa to darbepoetin alfa is 200 units to 1 µg. However, this may result in the over treatment of uraemic anaemia.Methods: All in‐centre haemodialysis patients (n = 60) were converted from an existing subcutaneous epoetin alfa regimen to weekly intravenous darbepoetin alfa. The protocol for anaemia management included a target haemoglobin (Hb) concentration of 120–130 g/L and a ferritin of 300–600 µg/L. Patient treatments were converted from subcutaneous epoetin alfa to weekly, intravenous darbepoetin alfa at month 0, at a conversion dose of 200 units epoetin alfa to 1 µg darbepoetin.Results: Both Hb and ferritin concentrations remained within the target range, but darbepoetin dosages fell from 50.8 to 42.3 µg/week by month 3 (P = 0.02). The initial conversion factor of 210 units/µg rose to 275 units/µg (P = 0.01) at month 4. No difference in conversion dosage could be determined between patients who were epoetin sensitive (200 units/kg per week, P = NS). Patients were then switched to fortnightly darbepoetin alfa dosing treatments; the existing weekly dose being doubled and Hb levels fell from 125 to 110 g/L (P < 0.0001), despite an increase in the mean dose from 44.9 to 47.5 µg/week (P = 0.02).Conclusion: The original dosage reduction after the switch from epoetin alfa to weekly intravenous darbepoetin alfa may offset the increased relative cost of the latter. When administered weekly and intravenously, darbepoetin alfa maintains Hb at a more favourable conversion rate than is currently recommended.
- 1 August 2004
- Published by Wiley in Nephrology
- Vol. 9 (4) , 223-228
What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials?
SUMMARY: Background: The recommended conversion dose for changing from epoetin alfa to darbepoetin alfa is 200 units to 1 µg. However, this may result in the over treatment of uraemic anaemia.Methods: All in‐centre haemodialysis patients (n = 60) were converted from an existing subcutaneous epoetin alfa regimen to weekly intravenous darbepoetin alfa. The protocol for anaemia management included a target haemoglobin (Hb) concentration of 120–130 g/L and a ferritin of 300–600 µg/L. Patient treatments were converted from subcutaneous epoetin alfa to weekly, intravenous darbepoetin alfa at month 0, at a conversion dose of 200 units epoetin alfa to 1 µg darbepoetin.Results: Both Hb and ferritin concentrations remained within the target range, but darbepoetin dosages fell from 50.8 to 42.3 µg/week by month 3 (P = 0.02). The initial conversion factor of 210 units/µg rose to 275 units/µg (P = 0.01) at month 4. No difference in conversion dosage could be determined between patients who were epoetin sensitive (200 units/kg per week, P = NS). Patients were then switched to fortnightly darbepoetin alfa dosing treatments; the existing weekly dose being doubled and Hb levels fell from 125 to 110 g/L (P < 0.0001), despite an increase in the mean dose from 44.9 to 47.5 µg/week (P = 0.02).Conclusion: The original dosage reduction after the switch from epoetin alfa to weekly intravenous darbepoetin alfa may offset the increased relative cost of the latter. When administered weekly and intravenously, darbepoetin alfa maintains Hb at a more favourable conversion rate than is currently recommended.
- 1 January 2004
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 15 (1) , 148-156
Effects of Early and Late Intervention with Epoetin α on Left Ventricular Mass among Patients with Chronic Kidney Disease (Stage 3 or 4)
It is not known whether prevention of anemia among patients with chronic kidney disease would affect the development or progression of left ventricular (LV) hypertrophy. A randomized controlled trial was performed with 155 patients with chronic kidney disease (creatinine clearance, 15 to 50 ml/min), with entry hemoglobin concentrations ([Hb]) of 110 to 120 g/L (female patients) or 110 to 130 g/L (male patients). Patients were monitored for 2 yr or until they required dialysis; the patients were randomized to receive epoetin alpha as necessary to maintain [Hb] between 120 and 130 g/L (group A) or between 90 and 100 g/L (group B). [Hb] increased for group A (from 112 +/- 9 to 121 +/- 14 g/L, mean +/- SD) and decreased for group B (from 112 +/- 8 to 108 +/- 13 g/L) (P < 0.001, group A versus group B). On an intent-to-treat analysis, the changes in LV mass index for the groups during the 2-yr period were not significantly different (2.5 +/- 20 g/m(2) for group A versus 4.5 +/- 20 g/m(2) for group B, P = NS). There was no significant difference between the groups in 2-yr mean unadjusted systolic BP (141 +/- 14 versus 138 +/- 13 mmHg) or diastolic BP (80 +/- 6 versus 79 +/- 7 mmHg). The decline in renal function in 2 yr, as assessed with nuclear estimations of GFR, also did not differ significantly between the groups (8 +/- 9 versus 6 +/- 8 ml/min per 1.73 m(2)). In conclusion, maintenance of [Hb] above 120 g/L, compared with 90 to 100 g/L, had similar effects on the LV mass index and did not clearly affect the development or progression of LV hypertrophy. The maintenance of [Hb] above 100 g/L for many patients in group B might have been attributable to the relative preservation of renal function.
- 1 January 2004
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 15 (1) , 148-156
Effects of Early and Late Intervention with Epoetin α on Left Ventricular Mass among Patients with Chronic Kidney Disease (Stage 3 or 4)
It is not known whether prevention of anemia among patients with chronic kidney disease would affect the development or progression of left ventricular (LV) hypertrophy. A randomized controlled trial was performed with 155 patients with chronic kidney disease (creatinine clearance, 15 to 50 ml/min), with entry hemoglobin concentrations ([Hb]) of 110 to 120 g/L (female patients) or 110 to 130 g/L (male patients). Patients were monitored for 2 yr or until they required dialysis; the patients were randomized to receive epoetin alpha as necessary to maintain [Hb] between 120 and 130 g/L (group A) or between 90 and 100 g/L (group B). [Hb] increased for group A (from 112 +/- 9 to 121 +/- 14 g/L, mean +/- SD) and decreased for group B (from 112 +/- 8 to 108 +/- 13 g/L) (P < 0.001, group A versus group B). On an intent-to-treat analysis, the changes in LV mass index for the groups during the 2-yr period were not significantly different (2.5 +/- 20 g/m(2) for group A versus 4.5 +/- 20 g/m(2) for group B, P = NS). There was no significant difference between the groups in 2-yr mean unadjusted systolic BP (141 +/- 14 versus 138 +/- 13 mmHg) or diastolic BP (80 +/- 6 versus 79 +/- 7 mmHg). The decline in renal function in 2 yr, as assessed with nuclear estimations of GFR, also did not differ significantly between the groups (8 +/- 9 versus 6 +/- 8 ml/min per 1.73 m(2)). In conclusion, maintenance of [Hb] above 120 g/L, compared with 90 to 100 g/L, had similar effects on the LV mass index and did not clearly affect the development or progression of LV hypertrophy. The maintenance of [Hb] above 100 g/L for many patients in group B might have been attributable to the relative preservation of renal function.
- 1 May 2002
- Published by Wiley in Nephrology
- Vol. 7, S71-S72
Cardiovascular and musculoskeletal rehabilitation in progressive renal insufficiency
- 1 May 2002
- Published by Wiley in Nephrology
- Vol. 7, S71-S72
Cardiovascular and musculoskeletal rehabilitation in progressive renal insufficiency